natco pharma semaglutide to Launch Generic Injection in India in March 2026 Semaglutide 4 Mg / 3ML

Consistency at a "good enough" time beats constantly chasing the theoretically "perfect" time

An oral formulation of semaglutide was recently developed for clinical use, based on co-formulation with SNAC (sodium N -[8-(2-hydroxybenzoyl)amino] caprylate)

[1] [3] Patients should be advised to follow administration instructions carefully to maximise absorption

Pharmacokinetic modeling studies, small observational real-world analyses, and expert opinions from healthcare professionals suggest that some GLP-1 receptor activity and metabolic benefits may persist even when dosing intervals are extended

Both medications have their roles in obesity management, and the choice between the two will often fall on individual patient needs, preferences, medical history, and a healthcare providers recommendation

Fibrates remain first-line for severe hypertriglyceridemia (500 mg/dL) to prevent pancreatitis